News on Medial

Video telematics startup Cautio raises Rs 6.5 Cr in pre-seed round

EntrackrEntrackr · 1y ago
Video telematics startup Cautio raises Rs 6.5 Cr in pre-seed round
Medial

Video telematics startup Cautio has raised Rs 6.5 crore ($780k) in its pre-seed round led by Antler, 8i and AU Bank. The funding, a mix of equity and debt, was led by Antler, 8i Ventures, and AU Small Finance Bank with additional participation from Cautio’s early customers and angel investors. The startup will use the proceeds to escalate its efforts in deploying safety solutions across the country. Founded by Ankit Acharya and Pranjal Nadhani, Cautio offers cost-effective video telematics products and delivers tailored solutions aimed at mitigating safety issues prevalent in India. Through customizable dash cam devices and an AI-powered operating system, Cautio ensures accountability, improves driver conduct, minimises revenue loss, and adopts an API-first strategy. The startup counts among its clients institutions, mobility and logistic companies. It is also actively involved in multiple pilot projects across the country. Safe Cams, LightMetrics and Hero Group’s Qubo are some of the leading companies in this space.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 1d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.